Severe adverse skin reaction and desensitization to sorafenib

Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization

“…The incidence of DHRs to PKIs is unknown and some cases of IDHRs, such as urticaria and angioedema [58][59][60][61], as well as NIDHR, have been reported. The most frequent NIDHR are MPE and non-immediate urticaria [62][63][64], although some cases of SJS induced by regorafenib (inhibitor of vascular endothelial growth factor receptor [VEGFR]), ribociclib and palbociclib (inhibitors of cyclin-dependent protein kinases [DCK]) have been described [65,66].…”

“…Desensitization appears to be a safety and efficacy option for treatment of DHR to some PKI (imatinib, crizotinib, sunitinib, sorafenib,alectinib, regorafenib and dabrafenib) [58,[61][62][63][64]67,137].…”

Successful Desensitization to Sorafenib and Imatinib—A Report of Two Cases and a Literature Review

“…The patient underwent a 24-day desensitization protocol, and his initial positive skin prick test became negative after desensitization. Regarding sorafenib, we found only two reports of sorafenib desensitization in the literature [ 5 , 8 ]. Linauskiene et al described the case of a 21-year-old woman who developed fever and urticaria 10 days after the start of sorafenib therapy for metastatic lamellar hepatocellular carcinoma in a dosage of 800 mg daily [ 5 ].…”

“…Regarding sorafenib, we found only two reports of sorafenib desensitization in the literature [ 5 , 8 ]. Linauskiene et al described the case of a 21-year-old woman who developed fever and urticaria 10 days after the start of sorafenib therapy for metastatic lamellar hepatocellular carcinoma in a dosage of 800 mg daily [ 5 ]. The desensitization was performed using premedication (20 mg of prednisolone and antihistamines), reaching the cumulative dose of 2 × 400 mg between the fifth and seventh days.…”

“…Successful desensitization protocols have been described for different agents, most commonly for antibiotics, biologics, antineoplastic drugs, progesterone and aspirin/nonsteroidal anti-inflammatory drugs [ 4 ]. Few cases of desensitization to sorafenib and imatinib have been described in the literature so far [ 5 , 6 , 7 , 8 , 9 , 10 , 11 ].…”